Sun Pharmaceutical Industries share news, announcements and annual reports
NSE: SUNPHARMABSE: 524715Pharmaceuticals & BiotechnologyLarge Cap
Sun Pharmaceutical Industries Limited · Formerly Sun Pharmaceuticals Industries · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 1994 on BSE, Feb 1995 on NSE
Last close ₹1,777.70up ₹16.70 (0.95%)BSE ₹1,778.25
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,761.00.
30 Oct: open ₹1,769.00, high ₹1,855.00, low ₹1,766.20
52-week range of traded prices to 30 Oct 2026
₹1,583.70Low, 29 Jan 2026₹2,046.90High, 31 Jul 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹4,26,530 Cr13th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.90
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 32.99
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.78
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.90%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.1%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹1,962 crore of one-off items, the largest of them in the quarter to Sep 2026.
- 15.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 16.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.03
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 51,30,21833.2% delivered
Sun Pharmaceutical Industries share news and announcements
1,452 announcements, routine notices left out, newest first. Page 28 of 30.
Sep 2008
23 Sep · Change in shareholding
Sun Pharmaceuticals Industries Ltd has submitted revised shareholding pattern for the quarter ended June 30, 2008. Further the Company has informed the Exchange that there was error under clause 1(a) of category A i.e. Shareholding of promoter and promoter group for Individuals / Hindu Undivided Family wherein we have mentioned the total no of shares as 30534982 instead of 30531532 and in respect of Mr. Jayant Shantilal Sanghvi, the total no of shares was wrongly mentioned as 876634 instead of 873184 shares. A copy of the Revised Shareholding Pattern shall be available on the NSE website.8 Sep · Meeting
Proceedings of the Annual General Meeting of the Company held on September 06, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.4 Sep · Business
Press release dated September 03, 2008, titled "Sun Pharmaceutical Extends Tender Offer for Taro". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Aug 2008
27 Aug · Business
Press releases dated August 27, 2008, titled "Sun To File Amendment to Tender Offer for Taro Waiving Certain Conditions" and "Tel-Aviv Court Rules in Favor of Sun Pharmaceutical; No Special Tender Offer Necessary in Taro Offer". A copy of the press releases shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Aug · Business
Press release dated August 14, 2008, titled "Sun Pharma Announces U.S. FTC Clearance for Taro Tender Offer". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2008
30 Jul · Business
Vides it letter dated July 29, 2008 regarding the press release dated July 28, 2008, titled "Sun Pharma reaffirms commitment to Taro Facilities and employees". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Jul · Business
Press release dated July 30 2008, titled "Sun Pharma gets USFDA approval for generic Depakote (R) delayed release tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.29 Jul · Meeting
Annual General Meeting of the Company is scheduled to be held on September 06, 2008.28 Jul · Business
Press release dated July 28, 2008, titled "A quarter of all-round strong growth, Sales up 66%, Profit up 121%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 67081 lacs for quarter ending on 30-JUN-2008 against Rs. 50881 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 28078 lacs for the quarter ending on 30-JUN-2008 against Rs. 22539 lacs for the quarter ending on 30-JUN-2007.15 Jul · Business
Vides its letter dated July 15, 2008 regarding the press release relating to extension of the expiration date of the ongoing tender offer for shares of Taro Pharmaceutical Industries Ltd by a subsidiary of Sun Pharmaceutical Industries Ltd. Further the copy of the press release dated July 14, 2008, titled "Sun Pharma Extends Tender Offer for Taro" shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Jul · Business
Press release dated July 12, 2008, titled "Sun Pharma to announce Q1 2008-09 results on July 28, 2008". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Jul · Board meeting
Meeting on 28 Jul 2008: “Unaudited Financial Results for the Qtr ended June 30, 2008”
Jun 2008
30 Jun · Business
Press release dated June 30, 2008, titled "Sun Pharma Commences All Cash Tender Offer to Purchase Taro Ordinary Shares for USD 7.75 Per Share". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.26 Jun · Business
Press release dated June 26, 2008, titled "Sun Pharmaceutical Exercises its Options to Acquire the Shares of the Controlling Shareholders of Taro Pharmaceuticals". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Jun · Business
Press release dated June 24, 2008, titled "Sun Pharmaceutical Sends Second Letter to Taro Pharmaceutical Regarding Taro's Irish Subsidiary". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Jun · News Verification
News Verification : The media had reports that Sun Pharmaceuticals Industries Ltd may acquire a substantial stake in Torrent Pharmaceuticals. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Sun Pharmaceuticals Industries Ltd has vide its letter inter-alia stated,"We are not looking for any domestic acquisitions and we do not comment on any market rumours."5 Jun · Business
Press release dated June 05, 2008, titled "Sun Pharma Comments on Taro's Potential Sale of its Irish Operations". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
May 2008
30 May · Business
Press release dated May 30, 2008, titled "Strong US growth on the back of first to file opportunities; Robust Growth in India; Q4 Sales growth 129%, Profit Increase 225%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 May · Dividend
Board of Directors of the Company at its meeting held on May 30, 2008 has recommended payment of dividend @ 210% on the equity shares of the Company for the year ended March 31, 2008 subject to the approval of the members at the ensuing Annual General Meeting of the Company. Further the Register of Members and Share Transfer Books of the Company will be closed from August 27, 2008 to September 06, 2008 (both days inclusive) for the purpose of payment of dividend.30 May · Results
Consolidated Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 125717 lacs for quarter ending on 31-MAR-2008 against Rs. 54419 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 72281 lacs for the quarter ending on 31-MAR-2008 against Rs. 21208 lacs for the quarter ending on 31-MAR-2007.30 May · Results
Standalone Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 58164 lacs for quarter ending on 31-MAR-2008 against Rs. 43064 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 24789 lacs for the quarter ending on 31-MAR-2008 against Rs. 15567 lacs for the quarter ending on 31-MAR-2007.30 May · Results
Standalone Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 236564 lacs for year ending on 31-MAR-2008 against Rs. 166256 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 101404 lacs for the year ending on 31-MAR-2008 against Rs. 62893 lacs for the year ending on 31-MAR-2007.30 May · Results
Consolidated Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 335653 lacs for year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 148690 lacs for the year ending on 31-MAR-2008.29 May · Business
Press release dated May 29, 2008, titled "Sun Pharma Responds to Taro's purported Termination of Merger Agreement". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.28 May · Updates
Receipt of notice from Taro Pharmaceutical Industries Ltd for termination of Merger Agreement with the Company (Sun Pharma)'s subsidiary, Alkaloida Chemical Company Exclusive Group Ltd. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 May · Board meeting
Interalia, (1) to consider the audited financial results of the Company for the year ended March 31, 2008. (2) to consider recommendation of payment of dividend on equity shares for the year ended March 31, 2008 subject to the approval of the shareholders at the ensuing Annual General Meeting.20 May · Business
Press release dated May 17, 2008, titled "Sun Pharma to announce Q4 2007-08 results on May 30, 2008". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 May · Results
Company shall be publishing the Audited Annual Accounts/ Results for the year ended March 31, 2008 within the stipulated time period of three months of closure of the financial year i.e. by June 30, 2008. Accordingly the un-audited financial results for the fourth quarter / year ended March 31, 2008 will not be published by the Company.
Mar 2008
31 Mar · Business
Press release dated March 31, 2008, titled "Sun Pharmaceutical announces launch of generic Ethyol; Enjoys 180 day marketing exclusivity on this first-to-file ANDA with para IV certification". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.24 Mar · Allotment of Equity Shares
Pursuant to the terms and conditions of the Offering Circular dated November 24, 2004 the committee of Directors (Allotment) of the Company at its meeting held on March 20, 2008 has allotted 25,18,834 (Twenty Five Lacs Eighteen Thousand Eight Hundred Thirty Four) Equity shares of Rs 5/- each of the Company at a premium of Rs.724.30 per share upon exercise of option of conversion for 40813 - Zero Coupon foreign Currency Convertible Bonds of US $ 1000 each (FCCB) in to Equity shares of the Company by FCCB holders. Consequently, the paid up Equity Share Capital of the Company has increased from 20,45,97, 557 Equity shares of Rs. 5/- each to 20,71,16,391 Equity shares of Rs. 5/- each as of date. The entire 350,000 - Zero Coupon Foreign Currency Convertible Bonds due 2009 of US $ 1000 each (FCCB) aggregating to US $ 350 Million issued by the company have been converted in to Equity shares of Rs 5/- each of the company and hence, there is no FCCB outstanding as on date.24 Mar · Business
Press release dated March 21, 2008, titled "Sun Pharmaceutical announces USFDA approval to market generic Tessalon(R)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.19 Mar · Business
Press release dated March 19, 2008, titled "Sun Pharmaceutical announces USFDA approval to market generic Cerebyx(R)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.17 Mar · Business
Press release dated March 15, 2008, titled "Sun Pharmaceutical announces USFDA approval to market generic Ethyol(R)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.6 Mar · Business
Press release dated March 05, 2008, titled "Sun Pharma gets USFDA tentative approval for generic Gemzar(R) injection". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Mar · Allotment of Equity Shares
Pursuant to the terms and conditions of the offering Circular dated November 24, 2004, the committee of Directors(allotment) of the Company at its meeting held on March 01,2008 has allotted 31,20,084 (Thirty One Lacs Twenty Thousand Eighty Four) Equity shares of Rs 5/- each of the Company at a premium of Rs724.30 per share upon exercise of option of conversion for 50,555 Zero Coupon Foreign Currency Convertible Bonds of US $ 1000 each (FCCB) in to Equity shares of the Company by FCCB holders. Consequently, the paid up Equity share capital of the Company has increased from 20,14,77,473 Equity shares of Rs 5/- each to 20,45,97,557 Equity shares of Rs 5/- each as of date.
Feb 2008
27 Feb · Release
Release dated February 27, 2008, titled "Sun Pharma gets USFDA approval to market generic Demadex Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.20 Feb · Business
Press release dated February 19, 2008, titled "Sun Pharma buys Taro Pharma shares from Brandes". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Feb · Business
Press release dated February 14, 2008, titled "Sun Pharma gets USFDA tentative approval for generic Depakote(R) delayed release tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.14 Feb · Foreign Currency Convertible Bonds
In accordance with the terms of issue of Zero Coupon Foreign Currency Convertible Bonds of US$ 1000/- each due 2009 (FCCBs), the Company has exercised its option and given required notice for early redemption of the remaining outstanding balance of 89,618 FCCBs aggregating to 89.618 Millions (after excluding 1,750 FCCBs aggregating 1.750 Million for which notices for conversion to equity shares have been received but resultant shares are yet to be allotted) being early redemption date notified as 27th March,2008. In view thereof, all outstanding FCCBs for which no option for conversion into equity shares have been exercised before 27th March, 2008 will be fully redeemed by the Company as per the terms of the issue of the FCCBs
Jan 2008
30 Jan · Release
Release dated January 30, 2008, titled "Sun Pharma reports strong performance Q3 FY08; Sales growth 49%, Profit Increased 60%, R&D spend at Rs 842 million". A copy of the release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.30 Jan · Results
Standalone Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 73391 lacs for quarter ending on 31-DEC-2007 against Rs. 41791 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 34593 lacs for the quarter ending on 31-DEC-2007 against Rs. 16513 lacs for the quarter ending on 31-DEC-2006.30 Jan · Results
Consolidated Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 80397 lacs for quarter ending on 31-DEC-2007 against Rs. 54004 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 31835 lacs for the quarter ending on 31-DEC-2007 against Rs. 19885 lacs for the quarter ending on 31-DEC-2006.30 Jan · Release
Release dated January 30, 2008, titled "Sun Pharma launches generic Protonix Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.25 Jan · Allotment of Equity Shares
Vide its letter dated January 25, 2008, that: "Pursuant to the terms and conditions of the Offering Circular dated November 24, 2004, the Committee of Directors (Allotment) of the Company at its meeting held today, has allotted 30,858 (Thirty Thousand Eight Hundred and Fifty Eight) Equity Shares of Rs.5/- each of the Company at a premium of Rs.724.30 per share upon exercise of option of conversion for 500 Zero Coupon Foreign Currency Convertible Bonds of US $ 1000 each (FCCB) into Equity shares of the Company by FCCB holder. Consequently, the paid up Equity Share Capital of the Company has increased from 20,14,46,615 Equity Shares of Rs.5/- each to 20,14,77,473 Equity Shares of Rs.5/- each, as of date".17 Jan · Business
Press release dated January 16, 2008, titled "Sun Pharma to announce Q3 2007-08 results on January 30, 2008". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.16 Jan · Board meeting
Interalia, to consider and take on record the un-audited financial results of the Company for the third quarter ended December 31, 2007.
Dec 2007
31 Dec · Allotment of Equity Shares
Vide its letter dated December 29, 2007, that: "Pursuant to the terms and conditions of the Offering Circular dated November 24, 2004, the Committee of Directors (Allotment) of the Company at its meeting held on today, has allotted 339,439 (Three Lacs Thirty Nine Thousand Four Hundred and Thirty Nine) Equity Shares of Rs.5/- each of the Company at a premium of Rs.724.30 per share upon exercise of option of conversion for 5,500 Zero Coupon Foreign Currency Convertible Bonds of US $ 1000 each (FCCB) into Equity shares of the Company by FCCB holder. Consequently, the paid up Equity Share Capital of the Company has increased from 20,11,07,176 Equity Shares of Rs.5/- each to 20,14,46,615 Equity Shares of Rs.5/- each, as of date".3 Dec · Allotment of Equity Shares
Pursuant to the terms and conditions of the Offering Circular dated November 24, 2004, the Committee of Directors (Allotment) of the Company at its meeting held on December 1, 2007, has allotted 208,599 (Two Lacs Eight Thousand Five Hundred and Ninety Nine) Equity Shares of Rs.5/- each of the Company at a premium of Rs.724.30 per share upon exercise of option of conversion for 3,380 Zero Coupon Foreign Currency Convertible Bonds of US $ 1000 each (FCCB) into Equity shares of the Company by FCCB holder. Consequently, the paid up Equity Share Capital of the Company has increased from 20,08,98,577 Equity Shares of Rs.5/- each to 20,11,07,176 Equity Shares of Rs.5/- each, as of date
Nov 2007
5 Nov · Allotment of Equity Shares
Pursuant to the terms and conditions of the Offering Circular dated November 24, 2004, the Committee of Directors (Allotment) of the Company at its meeting held on November 03, 2007, has allotted 5,09,161 (Five Lakhs Nine Thousand One Hundred and Sixty One) Equity Shares of Rs.5/- each of the Company at a premium of Rs.724.30 per share upon exercise of option of conversion for 8,250 Zero Coupon Foreign Currency Convertible Bonds of US $ 1000 each (FCCB) into Equity shares of the Company by FCCB holders. Consequently, the paid up Equity Share Capital of the Company has increased from 20,03,89,416 Equity Shares of Rs.5/- each to 200898577 Equity Shares of Rs.5/- each, as of date